Teacher Retirement System of Texas Purchases 8,600 Shares of Cencora, Inc. (NYSE:COR)

Teacher Retirement System of Texas boosted its stake in shares of Cencora, Inc. (NYSE:COR - Free Report) by 7.6% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 121,640 shares of the company's stock after acquiring an additional 8,600 shares during the period. Teacher Retirement System of Texas owned 0.06% of Cencora worth $27,330,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Raymond James Financial Inc. bought a new stake in shares of Cencora in the fourth quarter worth about $322,460,000. Wellington Management Group LLP raised its holdings in shares of Cencora by 7.0% during the 3rd quarter. Wellington Management Group LLP now owns 5,193,386 shares of the company's stock worth $1,168,927,000 after acquiring an additional 338,452 shares in the last quarter. Amundi boosted its position in shares of Cencora by 30.8% during the 4th quarter. Amundi now owns 1,338,710 shares of the company's stock valued at $318,385,000 after acquiring an additional 314,846 shares during the last quarter. Nordea Investment Management AB grew its holdings in shares of Cencora by 40.2% in the fourth quarter. Nordea Investment Management AB now owns 1,077,272 shares of the company's stock valued at $243,173,000 after purchasing an additional 308,773 shares in the last quarter. Finally, Two Sigma Advisers LP increased its position in Cencora by 21.7% in the third quarter. Two Sigma Advisers LP now owns 1,638,400 shares of the company's stock worth $368,771,000 after purchasing an additional 292,600 shares during the last quarter. 97.52% of the stock is currently owned by institutional investors.

Remove Ads

Insider Buying and Selling

In other news, EVP Silvana Battaglia sold 5,000 shares of the stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the transaction, the executive vice president now directly owns 15,374 shares in the company, valued at approximately $3,724,197.76. This trade represents a 24.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Lazarus Krikorian sold 2,000 shares of the business's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $260.06, for a total transaction of $520,120.00. Following the completion of the transaction, the chief accounting officer now directly owns 20,154 shares of the company's stock, valued at $5,241,249.24. This trade represents a 9.03 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 11,970 shares of company stock valued at $2,998,670 over the last quarter. 10.80% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. JPMorgan Chase & Co. lifted their price objective on shares of Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a research note on Friday, January 24th. Mizuho started coverage on Cencora in a research report on Wednesday, December 4th. They issued an "outperform" rating and a $280.00 price target for the company. Evercore ISI upped their price objective on Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a research report on Thursday, February 6th. StockNews.com upgraded Cencora from a "hold" rating to a "buy" rating in a report on Wednesday, March 12th. Finally, Wells Fargo & Company increased their price target on Cencora from $251.00 to $274.00 and gave the company an "equal weight" rating in a report on Friday, March 14th. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $280.20.

Cencora Trading Up 1.1 %

Cencora stock traded up $2.84 during mid-day trading on Wednesday, hitting $271.32. The company's stock had a trading volume of 1,036,117 shares, compared to its average volume of 1,378,648. Cencora, Inc. has a one year low of $214.77 and a one year high of $271.74. The stock has a market cap of $52.61 billion, a PE ratio of 38.59, a P/E/G ratio of 1.31 and a beta of 0.51. The company has a 50 day moving average of $251.80 and a 200-day moving average of $240.46. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92.

Cencora (NYSE:COR - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. On average, research analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Friday, February 14th were issued a $0.55 dividend. The ex-dividend date of this dividend was Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.81%. Cencora's payout ratio is 31.29%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.